My mom was just diagnosed with stage 2 triple negative breast cancer. What happens next

I'm so sorry to hear about your mom's diagnosis. This is a lot to process, but I want to help you understand what typically comes next.

Understanding Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer means the tumor tested negative for three key receptors:

• Estrogen receptor (ER-) - doesn't respond to estrogen
• Progesterone receptor (PR-) - doesn't respond to progesterone
• HER2-negative (HER2-) - doesn't have excess HER2 protein

According to NCCN Guidelines, this means hormone therapy and HER2-targeted drugs won't work for this cancer. Instead, chemotherapy is the primary treatment approach for TNBC.

What Typically Happens Next

1. Treatment Planning & Additional Testing

Your mom's oncology team will:

• Review all pathology results and imaging
• Determine the exact stage (size of tumor, lymph node involvement)
• Consider genetic testing for BRCA1/BRCA2 mutations - this is important because it can affect treatment options
• Discuss whether surgery or chemotherapy comes first

2. Two Main Treatment Approaches

Option A: Surgery First

• Lumpectomy (removing just the tumor) or mastectomy (removing the breast)
• Followed by chemotherapy to eliminate any remaining cancer cells
• Then radiation therapy if needed

Option B: Chemotherapy First (Neoadjuvant)

• Chemotherapy given before surgery to shrink the tumor
• This approach is increasingly common for TNBC
• According to NCCN Guidelines, one preferred regimen includes pembrolizumab (an immunotherapy) combined with chemotherapy
• Surgery follows after the tumor shrinks
• Additional treatment based on how well the cancer responded

3. Why Chemotherapy First Might Be Recommended

For TNBC specifically, starting with chemotherapy can:

• Shrink the tumor, potentially allowing for less extensive surgery
• Show how well the cancer responds to treatment
• Provide important information for additional treatment decisions
• In some cases, eliminate all detectable cancer before surgery

Important Treatment Details for TNBC

According to NCCN Guidelines, pembrolizumab-based regimens are a preferred approach for TNBC. This combines:

• Immunotherapy (pembrolizumab) - helps the immune system fight cancer
• Chemotherapy (typically carboplatin and paclitaxel, followed by doxorubicin or epirubicin with cyclophosphamide)

If cancer remains after treatment: Additional options like capecitabine (oral chemotherapy) may be recommended. If your mom has a BRCA mutation, olaparib (a targeted therapy) might also be an option.

Questions Your Mom Should Ask Her Oncologist

1. Do you recommend surgery first or chemotherapy first, and why?
2. Should I have genetic testing for BRCA1/BRCA2 mutations? When?
3. What specific chemotherapy regimen do you recommend for my case?
4. Am I a candidate for immunotherapy (pembrolizumab) with chemotherapy?
5. What are the expected side effects and how can we manage them?
6. What is the complete treatment timeline - how many months total?
7. How will you monitor whether the treatment is working?
8. What support services are available (nutrition, counseling, financial assistance)?

What You Can Do Now

• Attend appointments with your mom (or join virtually) to help take notes and ask questions
• Request copies of all pathology reports and test results
• Ask about fertility preservation if your mom is premenopausal and this is a concern
• Connect with support resources - many cancer centers have patient navigators who can help coordinate care
• Take things one step at a time - the treatment plan will become clearer after the first oncology consultation

Important to Know

While TNBC is considered aggressive, it also often responds well to chemotherapy. Many patients achieve excellent outcomes, especially when cancer is caught at stage 2. The addition of immunotherapy has improved treatment results for TNBC in recent years.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Patients: Invasive Breast Cancer, 2024; NCCN Guidelines for Patients: Inflammatory Breast Cancer, 2025